PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23144710-8	2012	A subset of NPC1 patients on miglustat, a glycosphingolipid synthesis inhibitor, showed significantly decreased levels of FABP3 compared to patients not on miglustat therapy.	miglustat	29-38	NPC intracellular cholesterol transporter 1	Homo sapiens	12-16	
23144710-8	2012	A subset of NPC1 patients on miglustat, a glycosphingolipid synthesis inhibitor, showed significantly decreased levels of FABP3 compared to patients not on miglustat therapy.	miglustat	156-165	NPC intracellular cholesterol transporter 1	Homo sapiens	12-16	
11013265-6	2000	Results using the inhibitor N-butyldeoxynojirimycin, which depletes cellular complex glycosphingolipids, demonstrates that the cholesterol trafficking defect in NPC1 cells is not caused by ganglioside accumulation.	miglustat	28-51	NPC intracellular cholesterol transporter 1	Homo sapiens	161-165	
33598405-4	2021	Case presentation: We describe our experience in a now 17-year-old female with NP-C manifest early in childhood who has been successfully and continuously treated with miglustat and KDT in a palliative care setting for 3y.	miglustat	168-177	NPC intracellular cholesterol transporter 1	Homo sapiens	79-83